Accera has commenced a clinical trial evaluating the efficacy of 26 weeks daily administration of AC-1204 compared with placebo in patients with mild-to-moderate Alzheimer’s disease (AD).

AC-1204 is caprylic triglyceride designed to improve cognitive function in mild-to-moderate Alzheimer’s disease.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Accera president and CEO Holger Kunze said following an investment from Nestlé Health Science, the company is keen to produce additional data demonstrating the effectiveness of the product in Alzheimer’s disease patients.

"AC-1204 is caprylic triglyceride designed to improve cognitive function in mild-to-moderate Alzheimer’s disease."

"We believe we have a truly innovative approach that will meet the needs of patients in this overwhelmingly underserved market," Kunze said.

The randomised, double-blind, multi-centre study is expected to enrol more than 400 patients at around 60 clinical sites in the US.

See Also:

Placebo-controlled, parallel-group trial will assess the effects of once daily dosing of AC-1204 for 26 weeks on cognition, pharmacokinetic measures, activities of daily living, resource utilisation and quality of life among subjects with mild-to-moderate AD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary endpoint of the study includes the effect of AC-1204 on memory and cognition based on the Alzheimer’s disease Assessment Scale-cognitive subscale after 26 weeks, among both carriers and non-carriers of the epsilon 4 variant of the gene apolipoprotein E.

Earlier studies established proof-of-concept for the company’s approach of tackling the physiological characteristic of the brain’s inability to optimally metabolise glucose by providing an alternative energy source for brain cells.